<?xml version="1.0" encoding="UTF-8"?>
<VIOLIN>
	<pathogen pathogen_id="pathogen60">
		<pathogen_name>Varicella-zoster virus</pathogen_name>
		<taxon_id>10335</taxon_id>
		<pathogenesis refs="reference746">VZV share much genome homology with the herpes simplex viruses (HSV). The capsid is surrounded by a number of loosely associated proteins known collectively as the tegument. Many of these tegument proteins play critical roles in initiating the process of virus reproduction in the infected cell. The tegument is in turn covered by a lipid envelope studded with glycoproteins that are displayed on the exterior of the virion (Wiki: Varicella zoster).</pathogenesis>
		<disease_name>chickenpox / shingles</disease_name>
		<protective_immunity refs=""></protective_immunity>
		<host_range refs=""></host_range>
		<introduction refs="reference746">Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella zoster virus is known by many names, including: chickenpox virus, varicella virus, zoster virus, and human herpes virus type 3 (HHV-3). It commonly causes chicken-pox in children and both shingles and postherpetic neuralgia in adults. Primary VZV infection results in chickenpox (varicella). After clinical symptoms of chickenpox have resolved, VZV remains dormant in the nervous system of the infected person (virus latency). In about 10-20% of cases, VZV reactivates later in life producing a disease known as herpes zoster or shingles. Serious complications of shingles include postherpetic neuralgia, zoster multiplex, myelitis, herpes ophthalmicus, or zoster sine herpete (Wiki: Varicella zoster).</introduction>
	</pathogen>

	<host host_id="host55">
		<common_name>Baboon</common_name>
		<scientific_name>Papio cynocephalus</scientific_name>
		<taxon_id>9556</taxon_id>
    </host>
	<host host_id="host43">
		<common_name>Bank vole</common_name>
		<scientific_name>Clethrionomys glareolus</scientific_name>
		<taxon_id>447135</taxon_id>
    </host>
	<host host_id="host31">
		<common_name>Bear</common_name>
		<scientific_name>Ursus americanus</scientific_name>
		<taxon_id>9643</taxon_id>
    </host>
	<host host_id="host51">
		<common_name>Birds</common_name>
		<scientific_name>Passeroidea</scientific_name>
		<taxon_id>175121</taxon_id>
    </host>
	<host host_id="host35">
		<common_name>Brown Trout</common_name>
		<scientific_name>Salmo trutta</scientific_name>
		<taxon_id>8032</taxon_id>
    </host>
	<host host_id="host30">
		<common_name>Buffalo</common_name>
		<scientific_name>Bison bison</scientific_name>
		<taxon_id>9901</taxon_id>
    </host>
	<host host_id="host53">
		<common_name>Carnivores</common_name>
		<scientific_name>Vulpes</scientific_name>
		<taxon_id>9625</taxon_id>
    </host>
	<host host_id="host37">
		<common_name>Cat</common_name>
		<scientific_name>Felis catus</scientific_name>
		<taxon_id>9685</taxon_id>
    </host>
	<host host_id="host52">
		<common_name>Catfishes</common_name>
		<scientific_name>Siluriformes</scientific_name>
		<taxon_id>7995</taxon_id>
    </host>
	<host host_id="host12">
		<common_name>Cattle</common_name>
		<scientific_name>Bos taurus</scientific_name>
		<taxon_id>9913</taxon_id>
    </host>
	<host host_id="host8">
		<common_name>Chicken</common_name>
		<scientific_name>Gallus gallus</scientific_name>
		<taxon_id>9031</taxon_id>
    </host>
	<host host_id="host42">
		<common_name>Chimpanzee</common_name>
		<scientific_name>Pan troglodytes</scientific_name>
		<taxon_id>9598</taxon_id>
    </host>
	<host host_id="host26">
		<common_name>chinchillas</common_name>
		<scientific_name>Chinchillidae</scientific_name>
		<taxon_id>10150</taxon_id>
    </host>
	<host host_id="host24">
		<common_name>Copper Pheasant</common_name>
		<scientific_name>Syrmaticus soemmerringii</scientific_name>
		<taxon_id>9067</taxon_id>
    </host>
	<host host_id="host29">
		<common_name>Deer</common_name>
		<scientific_name>Cervus elaphus</scientific_name>
		<taxon_id>9860</taxon_id>
    </host>
	<host host_id="host32">
		<common_name>Deer mouse</common_name>
		<scientific_name>Peromyscus maniculatus</scientific_name>
		<taxon_id>10042</taxon_id>
    </host>
	<host host_id="host36">
		<common_name>Dog</common_name>
		<scientific_name>Canis familiaris</scientific_name>
		<taxon_id>9615</taxon_id>
    </host>
	<host host_id="host9">
		<common_name>Ducks</common_name>
		<scientific_name>Anas</scientific_name>
		<taxon_id>8835</taxon_id>
    </host>
	<host host_id="host19">
		<common_name>Ferret</common_name>
		<scientific_name>Mustela putorius furo</scientific_name>
		<taxon_id>9669</taxon_id>
    </host>
	<host host_id="host48">
		<common_name>Fish</common_name>
		<scientific_name>Hyperotreti</scientific_name>
		<taxon_id>117565</taxon_id>
    </host>
	<host host_id="host41">
		<common_name>Gerbil</common_name>
		<scientific_name>Gerbillina</scientific_name>
		<taxon_id>10045</taxon_id>
    </host>
	<host host_id="host13">
		<common_name>Goat</common_name>
		<scientific_name>Capra hircus</scientific_name>
		<taxon_id>9925</taxon_id>
    </host>
	<host host_id="host47">
		<common_name>Gray wolf</common_name>
		<scientific_name>Canis lupus</scientific_name>
		<taxon_id>9612</taxon_id>
    </host>
	<host host_id="host7">
		<common_name>Guinea pig</common_name>
		<scientific_name>Cavia porcellus</scientific_name>
		<taxon_id>10141</taxon_id>
    </host>
	<host host_id="host16">
		<common_name>Hamster</common_name>
		<scientific_name>Mesocricetus auratus</scientific_name>
		<taxon_id>10036</taxon_id>
    </host>
	<host host_id="host18">
		<common_name>Horse</common_name>
		<scientific_name>Equus caballus</scientific_name>
		<taxon_id>9796</taxon_id>
    </host>
	<host host_id="host2">
		<common_name>Human</common_name>
		<scientific_name>Homo sapiens</scientific_name>
		<taxon_id>9606</taxon_id>
    </host>
	<host host_id="host39">
		<common_name>Macaque</common_name>
		<scientific_name>Macaca fascicularis</scientific_name>
		<taxon_id>9541</taxon_id>
    </host>
	<host host_id="host40">
		<common_name>Mongolian Gerbil</common_name>
		<scientific_name>Meriones unguiculatus</scientific_name>
		<taxon_id>10047</taxon_id>
    </host>
	<host host_id="host5">
		<common_name>Monkey</common_name>
		<scientific_name>Platyrrhini</scientific_name>
		<taxon_id>9479</taxon_id>
    </host>
	<host host_id="host3">
		<common_name>Mouse</common_name>
		<scientific_name>Mus musculus</scientific_name>
		<taxon_id>10090</taxon_id>
    </host>
	<host host_id="host59">
		<common_name>None</common_name>
		<scientific_name>None</scientific_name>
		<taxon_id></taxon_id>
    </host>
	<host host_id="host50">
		<common_name>Parrot</common_name>
		<scientific_name>Psittacidae</scientific_name>
		<taxon_id>9224</taxon_id>
    </host>
	<host host_id="host15">
		<common_name>Pig</common_name>
		<scientific_name>Sus scrofa</scientific_name>
		<taxon_id>9823</taxon_id>
    </host>
	<host host_id="host6">
		<common_name>Rabbit</common_name>
		<scientific_name>Oryctolagus cuniculus</scientific_name>
		<taxon_id>9986</taxon_id>
    </host>
	<host host_id="host45">
		<common_name>Rainbow trout</common_name>
		<scientific_name>Oncorhynchus mykiss</scientific_name>
		<taxon_id>8022</taxon_id>
    </host>
	<host host_id="host4">
		<common_name>Rat</common_name>
		<scientific_name>Rattus</scientific_name>
		<taxon_id>10114</taxon_id>
    </host>
	<host host_id="host34">
		<common_name>Raven</common_name>
		<scientific_name>Corvus corax</scientific_name>
		<taxon_id>56781</taxon_id>
    </host>
	<host host_id="host54">
		<common_name>sei whale</common_name>
		<scientific_name>Balaenoptera borealis</scientific_name>
		<taxon_id>9768</taxon_id>
    </host>
	<host host_id="host17">
		<common_name>Sheep</common_name>
		<scientific_name>Ovis aries</scientific_name>
		<taxon_id>9940</taxon_id>
    </host>
	<host host_id="host28">
		<common_name>Squirrel</common_name>
		<scientific_name>Spermophilus richardsonii</scientific_name>
		<taxon_id>37591</taxon_id>
    </host>
	<host host_id="host44">
		<common_name>Tree shrew</common_name>
		<scientific_name>Tupaiidae</scientific_name>
		<taxon_id>9393</taxon_id>
    </host>
	<host host_id="host49">
		<common_name>Trouts, salmons &amp; chars</common_name>
		<scientific_name>Salmoninae</scientific_name>
		<taxon_id>504568</taxon_id>
    </host>
	<host host_id="host38">
		<common_name>Turkey</common_name>
		<scientific_name>Meleagris gallopavo</scientific_name>
		<taxon_id>9103</taxon_id>
    </host>
	<host host_id="host33">
		<common_name>Vole</common_name>
		<scientific_name>Microtus ochrogaster</scientific_name>
		<taxon_id>79684</taxon_id>
    </host>
	<host host_id="host27">
		<common_name>Water buffalo</common_name>
		<scientific_name>Bubalus bubalis</scientific_name>
		<taxon_id>391902</taxon_id>
    </host>
	<vaccine vaccine_id="vaccine622">
		<vaccine_name>Priorix-Tetra</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Priorix-Tetra</brand_name>
		<manufacturer>GlaxoSmithKline</manufacturer>
		<vo_id>VO_0010735</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed>Canada</location_licensed>
		<description refs="">Products: Live virus. Other components: Lactose.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">Store at at 2 to 8Â°C. Do not freeze</storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine379">
		<vaccine_name>ProQuad</vaccine_name>
		<proper_name>Measles, Mumps, Rubella and Varicella Virus Vaccine Live</proper_name>
		<brand_name>ProQuad</brand_name>
		<manufacturer>Merck &amp; Co, Inc.</manufacturer>
		<vo_id>VO_0000091</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed>USA (License #0002)</location_licensed>
		<description refs="reference797">ProQuad is a sterile lyophilized preparation of (1) the components of M-M-R*II (Measles, Mumps and Rubella Virus Vaccine Live): Measles Virus Vaccine Live, a more attenuated line of measles virus, derived from Enders' attenuated Edmonston strain and propagated in chick embryo cell culture; Mumps Virus Vaccine Live, the Jeryl Lynnâ¢ (B level) strain of mumps virus propagated in chick embryo cell culture; Rubella Virus Vaccine Live, the Wistar RA 27/3 strain of live attenuated rubella virus propagated in WI-38 human diploid lung fibroblasts; and (2) Varicella Virus Vaccine Live (Oka/Merck) refrigerator-stable formulation, the Oka/Merck strain of varicella-zoster virus propagated in MRC-5 cells (FDA: ProQuad).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">maintained at a temperature of 2Â° to 8Â°C (36Â° to 46Â°F) or colder.</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference797">propagated in MRC-5 cells (FDA: ProQuad).</preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs=""></antigen>
		<host_response host_response_id="host_response473" host_id="host2">
			<immune_response refs="reference797">According to clinical trials, there were high levels of antibodies in 97.5% of those vaccinated after a single dose of Proquad (FDA: ProQuad).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs=""></protection_efficacy>
			<side_effects refs="">Side effects of vaccination include: injection site reactions, fever, irritability and diarrhea.</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine785">
		<vaccine_name>Varicella Subunit Vaccine encoding gI and gE glycoproteins</vaccine_name>
		<proper_name></proper_name>
		<brand_name></brand_name>
		<manufacturer></manufacturer>
		<vo_id>VO_0004153</vo_id>
		<type>Subunit vaccine</type>
		<status>Research</status>
		<vector></vector>
		<route>Intramuscular injection (i.m.)</route>
		<location_licensed></location_licensed>
		<description refs=""></description>
		<adjuvant refs="reference1251">Freund's adjuvant (Kimura et al., 1998).</adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Intramuscular injection (i.m.)</route>
		<antigen refs="reference1251">Recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) (Kimura et al., 1998).</antigen>

		<gene_engineering gene_engineering_id="gene_engineering245" gene_id="gene663">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>

		<gene_engineering gene_engineering_id="gene_engineering246" gene_id="gene662">
			<type>Recombinant protein preparation</type>
			<description refs=""></description>
		</gene_engineering>
		<host_response host_response_id="host_response545" host_id="host7">
			<immune_response refs=""></immune_response>
			<host_strain refs="">Hartley</host_strain>
			<vaccination_protocol refs="reference1251">Female Hartley guinea pigs (5 weeks old) were immunized with either a mixture of purified re- combinant gE and gI (25 Î¼g each) or the recombinant gE-gI complex (50 Î¼g). Purified protein solutions (0.25 mL) were injected intramuscularly with 0.25 mL of complete Freund's adjuvant at the first injection followed with incomplete Freund's adjuvant at the second and third injections at 2-week intervals. Control animals received 0.25 mL of PBS and an equal amount of adjuvant (Kimura et al., 1998).</vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference1251">In the gE-gI-immunized group, VZV was isolated from only 1 of 4 animals, and this animal had the lowest CMI and the lowest titer of anti-gE and anti-gI antibodies in the vitreous body. In contrast, VZV was isolated from 3 of 4 animals in the adjuvant-alone group (Kimura et al., 1998).</protection_efficacy>
			<side_effects refs=""></side_effects>
			<challenge_protocol refs="reference1251">To determine whether immunization with gE and gI can enhance the clearance of VZV in vivo, both immunized and control (adjuvant- alone) guinea pigs were challenged with VZV. Animals were inoculated intravitreally with 200 pfu of cell-associated VZV 4 weeks after the final immunization. At 4 h after inoculation, 4 animals from each group were sacrificed, and their eyes were harvested to test for infectious VZV (Kimura et al., 1998).</challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine640">
		<vaccine_name>Varilrix</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Varilrix</brand_name>
		<manufacturer>GlaxoSmithKline</manufacturer>
		<vo_id>VO_0010746</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed>Canada</location_licensed>
		<description refs="">Products: Live virus. Other components: Human albumin, Lactose.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">Store at 2-8Â°C (36-46Â°F).</storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine347">
		<vaccine_name>Varivax</vaccine_name>
		<proper_name>Varicella Virus Vaccine Live</proper_name>
		<brand_name>Varivax</brand_name>
		<manufacturer>Merck &amp; Co., Inc.</manufacturer>
		<vo_id>VO_0000119</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Intradermal injection (i.d.)</route>
		<location_licensed>USA (License #0002)</location_licensed>
		<description refs="">Indication: For active immunization of persons 12 months of age and older.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">DO NOT FREEZE, store at 2 to 8Â°C or colder (36 to 46Â°F or colder).</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference744">The OkaIMerck strain of live, attenuated varicella vlrus was initially obtained from a child with wild-type varicella, then introduced into human embryonic lung cell'cultures, adapted to and propagated in embryonic guinea pig cell cultures and finally propagated in human diploid cell cultures (WI-38). This live, attenuated varicella vaccine is a lyophllized preparation containing sucrose, phosphate, glutamate, processed gelatin, and urea as stabilizers. The product contains no preservative (FDA: Varivax).</preparation>
		<route refs="">Intradermal injection (i.d.)</route>
		<antigen refs="">OkaIMerck strain of live, attenuated varicella vlrus.</antigen>
		<host_response host_response_id="host_response440" host_id="host2">
			<immune_response refs="reference744">Clinical trials with several formulations of VARIVAX containing the attenuated  virus ranging from 1000 to 50,000 PFU per dose, have demonstrated that VARIVAX induces detectable immune responses and is generally well tolerated in healthy individuals ranging from 12 months to 55 years of age.  VARIVAX was also found to induce cell-mediated immune responses in vaccinees (FDA: Varivax).</immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference744">The majority of subjects who received the vaccine and were exposed to wild-type virus were either completely protected from chickenpox or developed a milder form of the disease.  Clinical studies have demonstrated continued protection up to 10 years after vaccination. Also, a boost in antibody levels has been observed in vaccinees following exposure to wild-type varicella as well as following a second dose of the vaccine (FDA: Varivax).</protection_efficacy>
			<side_effects refs="">Side effects of vaccination were mostly injection site redness and pain.</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<vaccine vaccine_id="vaccine641">
		<vaccine_name>Varivax III</vaccine_name>
		<proper_name></proper_name>
		<brand_name>Varivax III</brand_name>
		<manufacturer>Merck Frosst</manufacturer>
		<vo_id>VO_0010747</vo_id>
		<type>Live vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route>Subcutaneous injection</route>
		<location_licensed>Canada</location_licensed>
		<description refs="">Products: Live virus. Other components: Bovine serum, Glutamate, Residual protein from cell culture, Sucrose, Urea.</description>
		<adjuvant refs=""></adjuvant>
		<storage refs=""></storage>
		<virulence refs=""></virulence>
		<preparation refs=""></preparation>
		<route refs="">Subcutaneous injection</route>
		<antigen refs=""></antigen>
	</vaccine>
	<vaccine vaccine_id="vaccine348">
		<vaccine_name>Zostavax</vaccine_name>
		<proper_name>Zoster Vaccine, Live, (Oka/Merck)</proper_name>
		<brand_name>Zostavax</brand_name>
		<manufacturer>Merck &amp; Co., Inc.</manufacturer>
		<vo_id>VO_0000124</vo_id>
		<type>Live, attenuated vaccine</type>
		<status>Licensed</status>
		<vector></vector>
		<route></route>
		<location_licensed>USA (License #0002)</location_licensed>
		<description refs="reference745">Indication: Prevention of herpes zoster (shingles) in individuals 60 years of age and older when administered as a single-dose (FDA: Zostavax).</description>
		<adjuvant refs=""></adjuvant>
		<storage refs="">ZOSTAVAX SHOULD BE stored FROZEN at an average temperature of -15Â°C (+5Â°F) or colder.</storage>
		<virulence refs=""></virulence>
		<preparation refs="reference745">ZOSTAVAX is a lyophilized preparation of live, attenuated varicella-zoster virus (Oka/Merck) to be reconstituted with sterile diluent to give a single dose suspension with a minimum of 19,400 PFU (plaque forming units) when stored at room temperature for up to 30 minutes (FDA: Zostavax).</preparation>
		<route refs=""></route>
		<antigen refs="">live, attenuated varicella-zoster virus (Oka/Merck)</antigen>
		<host_response host_response_id="host_response443" host_id="host2">
			<immune_response refs=""></immune_response>
			<host_strain refs=""></host_strain>
			<vaccination_protocol refs=""></vaccination_protocol>
			<persistence refs=""></persistence>
			<immune_response_type refs=""></immune_response_type>
			<immune_response_type refs=""></immune_response_type>
			<protection_efficacy refs="reference745">According to clinical studies, ZOSTAVAX significantly reduced the risk of developing zoster when compared with placebo.  Vaccine efficacy for the prevention of herpes-zoster (HZ) was highest for those subjects 60-69
years of age and declined with increasing age (FDA: Zostavax).</protection_efficacy>
			<side_effects refs="reference745">The most common side effects reported included headache and injection site reactions (FDA: Zostavax).</side_effects>
			<challenge_protocol refs=""></challenge_protocol>
			<description refs=""></description>
		</host_response>
	</vaccine>
	<gene gene_id="gene663">
        <gene_name>ORF67</gene_name>
        <strain>Human alphaherpesvirus 3</strain>
        <vo_id>VO_0011247</vo_id>
        <ncbi_gene_id>1487689</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9625941</ncbi_protein_id>
        <gene_locus_tag>HHV3_gp68</gene_locus_tag>
        <gene_refseq>AF206304</gene_refseq>
        <protein_refseq>NP_040189</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10335</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>114495</gene_start>
        <gene_end>115591</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>envelope glycoprotein I</protein_name>
        <protein_pi>8.22</protein_pi>
        <protein_weight>36387.83</protein_weight>
        <protein_length>354</protein_length>
        <protein_note>envelope glycoprotein I; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share  four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA;virion envelope glycoproteins bind to cellular receptors; envelope glycoprotein E and glycoprotein I form a heterodimer that play important roles in virus cell-to-cell spread</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001348.1:114495-115591 Human herpesvirus 3, complete genome
GATGTTTTTAATCCAATGTTTGATATCGGCCGTTATATTTTACATACAAGTGACCAACGCTTTGATCTTC
AAGGGCGACCACGTGAGCTTGCAAGTTAACAGCAGTCTCACGTCTATCCTTATTCCCATGCAAAATGATA
ATTATACAGAGATAAAAGGACAGCTTGTCTTTATTGGAGAGCAACTACCTACCGGGACAAACTATAGCGG
AACACTGGAACTGTTATACGCGGATACGGTGGCGTTTTGTTTCCGGTCAGTACAAGTAATAAGATACGAC
GGATGTCCCCGGATTAGAACGAGCGCTTTTATTTCGTGTAGGTACAAACATTCGTGGCATTATGGTAACT
CAACGGATCGGATATCAACAGAGCCGGATGCTGGTGTAATGTTGAAAATTACCAAACCGGGAATAAATGA
TGCTGGTGTGTATGTACTTCTTGTTCGGTTAGACCATAGCAGATCCACCGATGGTTTCATTCTTGGTGTA
AATGTATATACAGCGGGCTCGCATCACAACATTCACGGGGTTATCTACACTTCTCCGTCTCTACAGAATG
GATATTCTACAAGAGCCCTTTTTCAACAAGCTCGTTTGTGTGATTTACCCGCGACACCCAAAGGGTCCGG
TACCTCCCTGTTTCAACATATGCTTGATCTTCGTGCCGGTAAATCGTTAGAGGATAACCCTTGGTTACAT
GAGGACGTTGTTACGACAGAAACTAAGTCCGTTGTTAAGGAGGGGATAGAAAATCACGTATATCCAACGG
ATATGTCCACGTTACCCGAAAAGTCCCTTAATGATCCTCCAGAAAATCTACTTATAATTATTCCTATAGT
AGCGTCTGTCATGATCCTCACCGCCATGGTTATTGTTATTGTAATAAGCGTTAAGCGACGTAGAATTAAA
AAACATCCAATTTATCGCCCAAATACAAAAACAAGAAGGGGCATACAAAATGCGACACCAGAATCCGATG
TGATGTTGGAGGCCGCCATTGCACAACTAGCAACGATTCGCGAAGAATCCCCCCCACATTCCGTTGTAAA
CCCGTTTGTTAAATAGAACTAATTATCCCGGATTTTATATTAAATAA

</dna_sequence>
        <protein_sequence>>NP_040189.1 envelope glycoprotein I [Human alphaherpesvirus 3]
MFLIQCLISAVIFYIQVTNALIFKGDHVSLQVNSSLTSILIPMQNDNYTEIKGQLVFIGEQLPTGTNYSG
TLELLYADTVAFCFRSVQVIRYDGCPRIRTSAFISCRYKHSWHYGNSTDRISTEPDAGVMLKITKPGIND
AGVYVLLVRLDHSRSTDGFILGVNVYTAGSHHNIHGVIYTSPSLQNGYSTRALFQQARLCDLPATPKGSG
TSLFQHMLDLRAGKSLEDNPWLHEDVVTTETKSVVKEGIENHVYPTDMSTLPEKSLNDPPENLLIIIPIV
ASVMILTAMVIVIVISVKRRRIKKHPIYRPNTKTRRGIQNATPESDVMLEAAIAQLATIREESPPHSVVN
PFVK

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Monoclonal antibodies to gI neutralize VZV in vitro in a complement- dependent manner [Ref1272:Keller et al., 1986]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [Ref1251:Kimura et al., 1998].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<gene gene_id="gene662">
        <gene_name>ORF68</gene_name>
        <strain>Human alphaherpesvirus 3</strain>
        <vo_id>VO_0011246</vo_id>
        <ncbi_gene_id>1487709</ncbi_gene_id>
        <ncbi_nucleotide_id></ncbi_nucleotide_id>
        <ncbi_protein_id>9625942</ncbi_protein_id>
        <gene_locus_tag>HHV3_gp69</gene_locus_tag>
        <gene_refseq>AH010255</gene_refseq>
        <protein_refseq>NP_040190</protein_refseq>
        <pdb_id></pdb_id>
        <xrefs></xrefs>
        <taxonomy_id>10335</taxonomy_id>
        <chromosome></chromosome>
        <segment></segment>
        <plasmid></plasmid>
        <gene_start>115807</gene_start>
        <gene_end>117720</gene_end>
        <gene_strand>+</gene_strand>
        <protein_name>envelope glycoprotein E</protein_name>
        <protein_pi>5.24</protein_pi>
        <protein_weight>64995.36</protein_weight>
        <protein_length>623</protein_length>
        <protein_note>envelope glycoprotein E; the Herpesviridae are non-segmented dsDNA viruses with genomes ranging from 120-230kbp; although herpes viruses vary greatly in sequence identity and homology, they all share  four common elements: an envelope, a tegument which is composed of viral enzymes, a capsid of 162 capsomers, and a core composed of genomic DNA;virion envelope glycoproteins bind to cellular receptors; envelope glycoprotein E and glycoprotein I form a heterodimer that play important roles in virus cell-to-cell spread</protein_note>
        <protein_annotation></protein_annotation>
        <dna_sequence>>NC_001348.1:115807-117720 Human herpesvirus 3, complete genome
TATGGGGACAGTTAATAAACCTGTGGTGGGGGTATTGATGGGGTTCGGAATTATCACGGGAACGTTGCGT
ATAACGAATCCGGTCAGAGCATCCGTCTTGCGATACGATGATTTTCACACCGATGAAGACAAACTGGATA
CAAACTCCGTATATGAGCCTTACTACCATTCAGATCATGCGGAGTCTTCATGGGTAAATCGGGGAGAGTC
TTCGCGAAAAGCGTACGATCATAACTCACCTTATATATGGCCACGTAATGATTATGATGGATTTTTAGAG
AACGCACACGAACACCATGGGGTGTATAATCAGGGCCGTGGTATCGATAGCGGGGAACGGTTAATGCAAC
CCACACAAATGTCTGCACAGGAGGATCTTGGGGACGATACGGGCATCCACGTTATCCCTACGTTAAACGG
CGATGACAGACATAAAATTGTAAATGTGGACCAACGTCAATACGGTGACGTGTTTAAAGGAGATCTTAAT
CCAAAACCCCAAGGCCAAAGACTCATTGAGGTGTCAGTGGAAGAAAATCACCCGTTTACTTTACGCGCAC
CGATTCAGCGGATTTATGGAGTCCGGTACACCGAGACTTGGAGCTTTTTGCCGTCATTAACCTGTACGGG
AGACGCAGCGCCCGCCATCCAGCATATATGTTTAAAACATACAACATGCTTTCAAGACGTGGTGGTGGAT
GTGGATTGCGCGGAAAATACTAAAGAGGATCAGTTGGCCGAAATCAGTTACCGTTTTCAAGGTAAGAAGG
AAGCGGACCAACCGTGGATTGTTGTAAACACGAGCACACTGTTTGATGAACTCGAATTAGACCCCCCCGA
GATTGAACCGGGTGTCTTGAAAGTACTTCGGACAGAAAAACAATACTTGGGTGTGTACATTTGGAACATG
CGCGGCTCCGATGGTACGTCTACCTACGCCACGTTTTTGGTCACCTGGAAAGGGGATGAAAAAACAAGAA
ACCCTACGCCCGCAGTAACTCCTCAACCAAGAGGGGCTGAGTTTCATATGTGGAATTACCACTCGCATGT
ATTTTCAGTTGGTGATACGTTTAGCTTGGCAATGCATCTTCAGTATAAGATACATGAAGCGCCATTTGAT
TTGCTGTTAGAGTGGTTGTATGTCCCCATCGATCCTACATGTCAACCAATGCGGTTATATTCTACGTGTT
TGTATCATCCCAACGCACCCCAATGCCTCTCTCATATGAATTCCGGTTGTACATTTACCTCGCCACATTT
AGCCCAGCGTGTTGCAAGCACAGTGTATCAAAATTGTGAACATGCAGATAACTACACCGCATATTGTCTG
GGAATATCTCATATGGAGCCTAGCTTTGGTCTAATCTTACACGACGGGGGCACCACGTTAAAGTTTGTAG
ATACACCCGAGAGTTTGTCGGGATTATACGTTTTTGTGGTGTATTTTAACGGGCATGTTGAAGCCGTAGC
ATACACTGTTGTATCCACAGTAGATCATTTTGTAAACGCAATTGAAGAGCGTGGATTTCCGCCAACGGCC
GGTCAGCCACCGGCGACTACTAAACCCAAGGAAATTACCCCCGTAAACCCCGGAACGTCACCACTTCTAC
GATATGCCGCATGGACCGGAGGGCTTGCAGCAGTAGTACTTTTATGTCTCGTAATATTTTTAATCTGTAC
GGCTAAACGAATGAGGGTTAAAGCCTATAGGGTAGACAAGTCCCCGTATAACCAAAGCATGTATTACGCT
GGCCTTCCAGTGGACGATTTCGAGGACTCGGAATCTACGGATACGGAAGAAGAGTTTGGTAACGCGATTG
GAGGGAGTCACGGGGGTTCGAGTTACACGGTGTATATAGATAAGACCCGGTGATCACCGAACCGGGGCAA
CGCCGAGCGTGTAAATTTAAATAA

</dna_sequence>
        <protein_sequence>>NP_040190.1 envelope glycoprotein E [Human alphaherpesvirus 3]
MGTVNKPVVGVLMGFGIITGTLRITNPVRASVLRYDDFHTDEDKLDTNSVYEPYYHSDHAESSWVNRGES
SRKAYDHNSPYIWPRNDYDGFLENAHEHHGVYNQGRGIDSGERLMQPTQMSAQEDLGDDTGIHVIPTLNG
DDRHKIVNVDQRQYGDVFKGDLNPKPQGQRLIEVSVEENHPFTLRAPIQRIYGVRYTETWSFLPSLTCTG
DAAPAIQHICLKHTTCFQDVVVDVDCAENTKEDQLAEISYRFQGKKEADQPWIVVNTSTLFDELELDPPE
IEPGVLKVLRTEKQYLGVYIWNMRGSDGTSTYATFLVTWKGDEKTRNPTPAVTPQPRGAEFHMWNYHSHV
FSVGDTFSLAMHLQYKIHEAPFDLLLEWLYVPIDPTCQPMRLYSTCLYHPNAPQCLSHMNSGCTFTSPHL
AQRVASTVYQNCEHADNYTAYCLGISHMEPSFGLILHDGGTTLKFVDTPESLSGLYVFVVYFNGHVEAVA
YTVVSTVDHFVNAIEERGFPPTAGQPPATTKPKEITPVNPGTSPLLRYAAWTGGLAAVVLLCLVIFLICT
AKRMRVKAYRVDKSPYNQSMYYAGLPVDDFEDSESTDTEEEFGNAIGGSHGGSSYTVYIDKTR

</protein_sequence>
        <phi_function>Protective antigen</phi_function>
        <phi_annotation>Monoclonal antibodies to gE  neutralize VZV in vitro in a complement- dependent manner [Ref1271:Wu and Forghani, 1997]. Guinea pigs immunized with recombinant varicella-zoster virus (VZV) glycoproteins E (gE) and I (gI) developed antigen-specific antibodies in the sera, vitreous, and conjunctival washes. Sera from immunized animals neutralized both cell-free and cell-associated VZV, and peripheral blood lymphocytes proliferated in vitro in response to recombinant gE and gI and to antigens from VZV-infected cells. Immunized guinea pigs were inoculated intravitreally with VZV, which induces chronic uveitis. VZV DNA was more rapidly cleared and infectious VZV was isolated less frequently from the retinas of animals immunized with gE and gI compared with that in controls receiving adjuvant alone [Ref1251:Kimura et al., 1998].</phi_annotation>
        <phi_function2></phi_function2>
        <phi_annotation2></phi_annotation2>
    </gene>
	<reference reference_id="reference797">
		<reference_name>FDA: ProQuad</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: ProQuad Vaccine</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094051.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference744">
		<reference_name>FDA: Varivax</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: Varivax vaccine information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094073.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference745">
		<reference_name>FDA: Zostavax</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>FDA: Zostavax vaccine information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/ucm094075.htm</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference924">
		<reference_name>GSK: Varilrix</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>GSK: Varilrix Product Information</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://www.gsk.ca/english/docs-pdf/varilrix_PM_20070110.pdf</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1272">
		<reference_name>Keller et al., 1986</reference_name>
		<reference_type>journal</reference_type>
		<authors>Keller PM, Lonergan K, Neff BJ, Morton DA, Ellis RW</authors>
		<title>Purification of individual varicella-zoster virus (VZV) glycoproteins gpI, gpII, and gpIII and their use in ELISA for detection of VZV glycoprotein-specific antibodies</title>
		<year>1986</year>
		<volume>14</volume>
		<issue>2</issue>
		<pages>177-188</pages>
		<journal_book_name>Journal of virological methods</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1251">
		<reference_name>Kimura et al., 1998</reference_name>
		<reference_type>journal</reference_type>
		<authors>Kimura H, Wang Y, Pesnicak L, Cohen JI, Hooks JJ, Straus SE, Williams RK</authors>
		<title>Recombinant varicella-zoster virus glycoproteins E and I: immunologic responses and clearance of virus in a guinea pig model of chronic uveitis</title>
		<year>1998</year>
		<volume>178</volume>
		<issue>2</issue>
		<pages>310-317</pages>
		<journal_book_name>The Journal of infectious diseases</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference746">
		<reference_name>Wiki: Varicella zoster</reference_name>
		<reference_type>website</reference_type>
		<authors></authors>
		<title>Wiki: Varicella zoster</title>
		<year></year>
		<volume></volume>
		<issue></issue>
		<pages></pages>
		<journal_book_name></journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url>http://en.wikipedia.org/wiki/Varicella_zoster</url>
		<file_name></file_name>
	</reference>
	<reference reference_id="reference1271">
		<reference_name>Wu and Forghani, 1997</reference_name>
		<reference_type>journal</reference_type>
		<authors>Wu L, Forghani B</authors>
		<title>Characterization of neutralizing domains on varicella-zoster virus glycoprotein E defined by monoclonal antibodies</title>
		<year>1997</year>
		<volume>142</volume>
		<issue>2</issue>
		<pages>349-362</pages>
		<journal_book_name>Archives of virology</journal_book_name>
		<publisher></publisher>
		<publisher_location></publisher_location>
		<book_editors></book_editors>
		<isbn></isbn>
		<university></university>
		<university_location></university_location>
		<degree></degree>
		<url></url>
		<file_name></file_name>
	</reference>
</VIOLIN>


